MIV Therapeutics Announces Online Availability of Presentation Detailing Company's Advanced Coronary Stent Coatings; Presentation Provides Overview of Proprietary Technology and Development of Novel Biocompatible and Drug-Eluting Coatings
The presentation was delivered by Dr. Tom Troczynski, MIVT's Vice President of Coatings, at the 4th European Symposium of Vascular Biomaterials in Strasbourg, France, held May 11-13, 2005. Discussed are applications and early laboratory results of MIVT's proprietary hydroxyapatite (HAp) coatings for vascular stents and other medical devices, which have been shown to provide superior biocompatibility and safety, as well as additional functionality for drug-eluting applications.
“Progress in Development of Composite Calcium Phosphate Coatings for Stents.”
The presentation covers MIVT's proprietary "Sol-Gel" aerosol-based technique for applying nano ultra-thin layers of the highly biocompatible HAp coating on vascular stents. It also describes MIVT's proprietary electro-chemical coating methods for applying thicker layers of HAp for use as a drug-delivery coating. The presentation includes high-resolution micro photographs that demonstrate the durability and flexibility of MIVT's HAp-coatings for stents.
Also summarized in the presentation are the results of several medical research studies that demonstrated the excellent performance and biomedical profiles of MIVT's HAp coatings. According to one conclusion reported by the authors regarding one of the studies: "The most important finding from this study is that the hydroxyapatite stent coating presents itself as uniquely biocompatible by comparison to polymeric stent coatings."
The report also summarizes results of animal-based studies that have consistently demonstrated HAp's high levels of biocompatibility and advanced performance. "Preliminary animal studies indicate excellent response of vascular tissue to the SG-HAp-coated stent surface. The processing and characterization results, as well as the results of preliminary animal studies, are extremely encouraging," said Dr. Troczynski.
Vascular stents are used to prop open narrowed or clogged blood vessels to restore healthy blood flow, however, there exist a number of potential complications that occur with current-generation stent technologies now in use. One such complication, called restenosis, is a re-narrowing of blood vessels following implantation of a stent. Recent medical studies reported in the Journal of the American Medical Association have shown that such complications occur at higher-than-expected rates in patients who receive current-generation stents, further underscoring the need for the creation of improved biocompatible and drug-eluting stents, such as the advanced technologies under development by MIVT.
To view the PowerPoint presentation on MIVT's HAp stent technology, please visit http://www.trilogy-capital.com/mivt_summary.aspx.
The presentation is titled, "Progress in Development of Composite Calcium Phosphate Coatings for Stents." It was co-authored by Arc Rajtar, MIVT's Vice President of Operations, and MIVT scientists M. Lien, D. Smith, D. Hakimi, Q. Yang, M. Tsui, and Dr. Troczynski, who is also Professor at the University of British Columbia.
About MIV Therapeutics
MIV Therapeutics is developing a next generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. The Company's ultra-thin coating has been derived from a unique biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technology provides an alternative solution to polymer-based drug eluting coatings currently in the stent market. A broader spectrum of synthetic parameters allows The Company's drug eluting coating easily and widely applicable to various implantable devices with a pre-designed drug release profile to meet desirable clinical performance. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 to Dr. Tom Troczynski for the development of hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development program.
For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Copyright (C) 2005 MIV Therapeutics Inc. All rights reserved.